Kezar topline lupus data disappoints

 

• Most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed

• Zetomipzomib demonstrates a favorable safety and tolerability profile, including in the PRESIDIO Open-label Extension Study where weekly zetomipzomib has been administered for up to an additional 77 weeks

• Topline data from MISSION Phase 2 trial of zetomipzomib in lupus nephritis (LN) is on track and expected in June 2022, consistent with previous guidance

https://www.marketscreener.com/quote/stock/KEZAR-LIFE-SCIENCES-INC-44315919/news/Kezar-Announces-Topline-Results-from-PRESIDIO-Trial-of-Zetomipzomib-for-the-Treatment-of-Dermatomyos-40259685/